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Abstract
Estrogen Receptor alpha (ERα) plays a major role in most breast cancers, and it is the target
of endocrine therapies used in the clinic as standard of care for women with breast cancer
expressing this receptor. The two methods ChIP-seq (chromatin immunoprecipitation cou-
pled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins)
have greatly improved our understanding of ERα function during breast cancer progression
and in response to anti-estrogens. A critical component of both ChIP-seq and RIME proto-
cols is the antibody that is used against the bait protein. To date, most of the ChIP-seq and
RIME experiments for the study of ERα have been performed using the sc-543 antibody
from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby
severely impacting the study of ERα in normal physiology as well as diseases such as
breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other com-
mercially available antibodies, and we show that 06–935 (EMD Millipore) and ab3575
(Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME
experiments.
Introduction
In the last decades, there has been significant interest in studying Estrogen Receptor alpha
(ERα) due to its causal role in more than three quarters of breast cancers[1]. Its key role in
breast cancer progression makes ERα the major target for endocrine therapies, which have
substantially improved patient survival. However, resistance to these therapies occurs in many
patients[2], which leads to incurable metastatic disease. Therefore, it is important to under-
stand the mechanisms underlying ERα action in cancer initiation as well as progression of the
disease. In addition, ERα plays an important role in development[3] and other diseases such as
ovarian cancer[4].
Our understanding of ERα-mediated gene transcription has evolved in recent years, due to
delineation of ERα-chromatin binding mechanisms through ChIP-seq (chromatin immuno-
precipitation followed by next generation sequencing) experiments[5–15]. It is now clear that
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differential binding of ERα to chromatin is associated with clinical outcome in primary ERα-
positive breast tumours[5], suggesting that changes in ERα binding mediates the altered gene
expression program that dictates endocrine responsiveness and clinical outcome. In addition
to changes in binding to chromatin, ERα transcriptional activity can be modulated by its asso-
ciation with different co-regulators and other associated transcription factors. Our lab has pre-
viously developed a method termed RIME (Rapid Immunoprecipitation of Endogenous
Proteins) for the study of protein complexes using mass spectrometry[16, 17]. A key compo-
nent of ERα ChIP-seq and RIME assays is the antibody that specifically and with high sensitiv-
ity targets ERα. Most ChIP-seq and RIME experiments have been performed using the ERα
antibody sc-543 from Santa Cruz Biotechnology[5, 9, 17–21]. This antibody has recently been
discontinued, impacting the ability to study ERα function in breast cancer as well as in other
diseases and physiological conditions. Here, we compare the sc-543 (Santa Cruz Biotechnol-
ogy) with other commercially available antibodies using breast cancer cells as a model and
demonstrate that 06–935 (EMD Millipore) and ab3575 (Abcam) antibodies can replace sc-543
in ChIP-seq and RIME assays.
Materials and methods
Cell culture
MCF7 cells were cultured in Dulbecco’s Modified Eagle Medium DMEM (Gibco, Thermo Sci-
entific) and MDA-MB-231 cells were grown in RPMI-1640 medium (Gibco, Thermo Scien-
tific). Both media conditions were supplemented with 10% foetal bovine serum (FBS), 50 U/
ml penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine. Cell lines were obtained from
ATCC (Middlesex). For both ChIP-seq and RIME experiments, 2x106 cells were seeded in 15
cm2 plates and collected at 80–90% confluency.
ChIP-Seq and RIME assays
The sc-543 (Santa Cruz), ab80922 (Abcam), ab3575 (Abcam), sc-514857 (C-3) (Santa Cruz
Biotechnology), C15100066 (Diagenode) and 06–935 (EMD Millipore) antibodies were used
for ChIP-qPCR. The sc-543, ab3575 and 06–935 antibodies were then used for ChIP-seq and
RIME. For each ChIP, 10μg of each of the antibodies sc-543, 06–935 and ab3575 or the rabbit
IgG ab37415 (Abcam) were used together with 100μl of Dynabeads Protein A (Invitrogen).
The antibody and the beads were incubated overnight at 4˚C with rotation. MCF7 cells were
fixed for 10 minutes using 1% formaldehyde (Thermo, #28908) and quenched with 0.1M gly-
cine. Cells were then washed and harvested in ice-cold PBS containing protease inhibitors
(Roche). In order to enrich for the nuclear fraction, pellets were resuspended in Lysis Buffer 1
(50mM Hepes–KOH, pH 7.5, 140mM NaCl, 1mM EDTA, 10% Glycerol, 0.5% NP-40/Igepal
CA-630, 0.25% Triton X-100) and rotated for 10 minutes, at 4˚C. Cells were then pelleted,
resuspended in Lysis buffer 2 (10mM Tris–HCL, pH8.0, 200mM NaCl, 1mM EDTA, 0.5mM
EGTA) and incubated for 5 minutes, at 4˚C with rotation. For both ChIP-seq and RIME
experiments, cells were pelleted, resuspended in 300 μl Lysis buffer 3 (10mM Tris–HCl, pH 8,
100mM NaCl, 1mM EDTA, 0.5mM EGTA, 0.1% Na–Deoxycholate) and sonicated using the
Bioruptor Pico sonicator (Diagenode, Liege, Belgium) for 10 cycles (30 seconds on, 30 seconds
off). After sonication the samples were centrifuged at maximum speed for 10 minutes at 4˚C
and a small aliquot of supernatant was kept as input for ChIP-seq. The rest of the supernatant
was added to the Protein A Dynabeads, which were incubated overnight with antibody. The
next day, the beads for ChIP-seq were washed six times with RIPA buffer (150mM NaCl,
10mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% NaDeoxycholate), followed by one wash
with TE (pH 7.4). Both ChIP samples and inputs were then de-crosslinked by adding 200 μl
ChIP-seq grade ER antibodies
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elution buffer (1% SDS, 0.1 M NaHCO3) overnight at 65˚C. After reverse crosslinking, DNA
was purified using the phenol-chloroform-isoamyl DNA extraction method. ChIP-seq and the
input libraries were prepared using the ThruPlex Sample Prep Kit (Illumina). ERα ChIP-seq
was performed in at least duplicates for each condition. For RIME, the antibody-bound beads
incubated with the chromatin samples were washed 10 times with RIPA buffer and twice with
100mM AMBIC (ammonium bicarbonate) prior to mass spectrometry analysis.
Sample preparation, LC-MS/MS analysis and data processing
A 10μL trypsin solution (15ng/ul) (Pierce) prepared in 100mM AMBIC was added to the
beads followed by overnight incubation at 37˚C. The next day, trypsin solution was added for
a second digestion step followed by incubation for 4h at 37˚C. At the end of the second step
digestion, the tubes were placed on a magnet and the supernatant solution was collected and
acidified by the addition of 2μl 5% formic acid. The peptides were cleaned with the Ultra-
Micro C18 Spin Columns (Harvard Apparatus) and were analysed in the Dionex Ultimate
3000 UHPLC system coupled with the Q-Exactive HF (Thermo Scientific) mass spectrometer.
Samples were loaded on the Acclaim PepMap 100, 100μm × 2cm C18, 5μm, 100A˙ trapping col-
umn with the ulPickUp injection method at loading flow rate 5μL/min for 10 min. For the
peptide separation the EASY-Spray analytical column 75μm × 25cm, C18, 2μm, 100 A˙ was
used for multi-step gradient elution. Mobile phase (A) was composed of 2% acetonitrile, 0.1%
formic acid, 5% dimethyl sulfoxide (DMSO) and mobile phase (B) was composed of 80% ace-
tonitrile, 0.1% formic acid, 5% DMSO. The full scan was performed in the Orbitrap in the
range of 400-1600m/z at 60K resolution. For MS2, the 10 most intense fragments were selected
at resolution 30K. A 2.0Th isolation window was used and the HCD collision energy was set
up at 28%. The HCD tandem mass spectra were processed with the SequestHT search engine
on Proteome Discoverer 2.2 software. The node for SequestHT included the following parame-
ters: Precursor Mass Tolerance 20ppm, Maximum Missed Cleavages sites 2, Fragment Mass
Tolerance 0.02Da and Dynamic Modifications were Oxidation of M (+15.995Da) and Deami-
dation of N, Q (+0.984Da). The Minora Feature Detector node was used for label-free quantifi-
cation and the consensus workflow included the Feature Mapper and the Precursor Ion
Quantifier nodes using intensity for the precursor quantification. The protein intensities were
normalized by the summed intensity separately for the IgG and ERα pull downs (within group
normalization). The plots for ERα coverage were created using the qPLEXanalyzer tool[22].
Heatmaps and PCA plot were done with the Phantasus Web tool (https://artyomovlab.wustl.
edu/phantasus/). The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange Consortium via the PRIDE[23] partner repository with the dataset identifier
PXD012930.
ChIP-seq data analysis
Reads were mapped to the GRCh38 genome using bwa version 0.7.12[24]. Prior to peak call-
ing, reads were filtered according to four criteria: (1) only reads aligning to canonical chromo-
somes (1–22, X, Y, MT) were considered for further analysis; (2) read aligning in blacklisted
regions were excluded[25]; (3) grey lists were generated using the R package GreyListChIP
and reads aligned in these regions were excluded; (4) reads with a mapping quality of less than
15 were excluded. Peak calling was carried out on each ChIP sample with MACS2 version
2.1.1.20160309 using the relevant input sample[26]. Peaks with a q-value < 0.01 were accepted
for further analysis. To create tag heatmaps, a consensus peak set was generated using the R
package DiffBind[5, 16]. The consensus peak set was composed of any peak that was called in
at least two samples. Motif analysis was carried out using AME[27] from the MEME suite
ChIP-seq grade ER antibodies
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version 4.12.0[28] and the HOCOMOCO Human (v10) motif database[29]. Sequences for
motif analysis for each sample were derived by selecting the top 1000 peaks by q-value from
the MACS2 peak set and then extracting the genomic sequence 500 bases either side of the
peak summits. A detailed description of the pipeline can be found in S1 File. ChIP-seq data
have been deposited in NCBI’s Gene Expression Omnibus[30] and are accessible through
GEO Series accession number GSE128208.
Results and discussion
ChIP-sequencing validates 06–935 and ab3575 as specific ERα antibodies
Given the discontinuation of anti-ERα antibody sc-543, we sought to validate alternatives for
immunoprecipitation experiments. We first compared the established sc-543 (Santa Cruz Bio-
technology) antibody with ab80922 (Abcam), ab3575 (Abcam), sc-514857 (C-3) (Santa Cruz
Biotechnology), C15100066 (Diagenode) and 06–935 (Millipore). For this purpose, we used
the ERα positive cell line MCF7 and performed ChIP-qPCR in biological duplicates (S1 Fig)
to assess ERα binding at known target regions (S1 Table).
The ChIP-qPCR comparison suggested that 06–935 (Millipore) and ab3575 (Abcam) could
successfully enrich ERα-bound chromatin at these selected loci and could therefore substitute for
sc-543. We performed ChIP-seq to compare these three antibodies in MCF7 cells using IgG as a
negative control. ERαChIP-seq was performed in at least duplicates for each condition, using the
same batch of chromatin, to ensure that antibodies could be directly compared. In addition, we
included the ERα negative MDA-MB-231 cell line in order to assess non-specific binding by these
antibodies. For MDA-MB-231, ChIP-seq was performed in biological triplicates.
We observed 6,031 ERα binding sites for sc-543 (Santa Cruz) antibody, 6,192 peaks for
ab3575 (Abcam) and 6,552 for 06–935 (Millipore). Importantly, none of these binding sites
were observed in the IgG negative control. The vast majority of sites identified in MCF7 cells
by sc-543 overlapped with those detected by ab3575 and 06–935 (Fig 1A). Consistently, we
found a strong correlation between the binding intensities for the three antibodies, which was
similar to the correlation between replicates for the same antibody (Fig 1B). All three antibod-
ies showed robust enrichment at binding sites compared to background and motif analysis
identified the ERα response element (ERE) as highly significantly enriched at these sites (Fig
1C). Importantly, neither of the ab3575 and 06–935 antibodies showed any significant enrich-
ment in the ERα negative cell line MDA-MB-231 (Fig 1C). In total, one peak was detected in
ER-negative cells using ab3575, two peaks for 06–935 and 124 binding sites for sc-543, con-
firming the specificity of the antibodies. Examples of ERα binding to previously described
ERα binding sites[16, 31] are illustrated in Fig 1D. Taken together, this indicates that the
ab3575 (Abcam) and 06–935 (Millipore) antibodies perform similarly to the sc-543 (Santa
Cruz) antibody in ChIP-seq experiments, both in terms of sensitivity and specificity.
Validation of 06–935 and ab3575 antibodies using RIME
We next sought to evaluate the performance of ab3575 (Abcam) and 06–935 (Millipore) in
RIME experiments to directly compare with the sc-543 (Santa Cruz) antibody, which has pre-
viously been successfully used in RIME experiments to explore the ERα interactome[9, 16, 22].
To this end, we tested the 06–935, ab3575 and sc-543 antibodies in two technical replicates
each using MCF7 cells. IgG controls were also analysed to discriminate specific associations
from non-specific interaction events.
To evaluate the pull-down efficiencies, we compared the sequence coverage of the bait pro-
tein obtained by the different antibodies. ERα was identified with a similar number of peptides
(Fig 2A) across the three different pull-downs, confirming that all three antibodies achieve
ChIP-seq grade ER antibodies
PLOS ONE | https://doi.org/10.1371/journal.pone.0215340 April 10, 2019 4 / 10
ChIP-seq grade ER antibodies
PLOS ONE | https://doi.org/10.1371/journal.pone.0215340 April 10, 2019 5 / 10
Fig 1. ChIP-seq comparison between Santa Cruz (sc-543), Millipore (06–935) and Abcam (ab3575) antibodies. A) Venn diagram showing
the overlap between ERα binding sites for Santa Cruz (sc-543), Millipore (06–935) and Abcam (ab3575) antibodies in MCF7 cells. B) Pearson’s
correlation between each replicate of all three antibodies in MCF7 cells. C) Top: De novo motif analysis of ERα binding sites using MEME.
Bottom: Heatmap of total number of ERα binding sites identified in both technical replicates of MCF7, and in all three biological replicates for
MDA-MB-231, respectively. D) Examples of ERα- bound regions. Tag densities are shown as reads per million.
https://doi.org/10.1371/journal.pone.0215340.g001
Fig 2. Comparison of RIME data between Santa Cruz (sc-543), Millipore (06–935) and Abcam (ab3575) antibodies. A) Protein sequence coverage of
ERα achieved by the use of Abcam (ab3575), Millipore (06–935) and Santa Cruz (sc-543) antibodies in RIME. B) PCA plot of known ERα interactors
(n = 319, BIOGRID and STRING databases) for the four different RIME pull-downs. C) Hierarchical clustering of the scaled intensities of known ERα
interactors from BIOGRID and STRING databases (n = 319). D) Hierarchical clustering of well-characterized ERα interactors.
https://doi.org/10.1371/journal.pone.0215340.g002
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efficient immunoprecipitation of the bait protein. Next, to compare the efficiency of the differ-
ent antibodies to detect known ERα interactors, we used a label-free quantification method
based on the Minora algorithm implemented in Proteome Discoverer 2.2 software (S2 File).
The PCA plot using intensities of known ERα-associated proteins (n = 319, BIOGRID and
STRING databases) across all four samples revealed a good separation between the ERα RIME
samples and the IgG controls, indicative of high specificity of all antibodies (Fig 2B). Impor-
tantly, we identify only minor differences between the three antibodies, suggesting that they all
efficiently pull down known ERα-associated proteins (Fig 2B and 2C). Specifically, amongst
the known ERα interactors we identified FOXA1, GATA3 and members of the p160 family that
were all highly enriched by all three antibodies (Fig 2D). Taken together, the three ERα anti-
bodies perform similarly in RIME experiments, enriching for well-known key ERα interactors.
Conclusions
Genome-wide analyses of ERα-chromatin binding sites using ChIP-based methods have expo-
nentially increased our knowledge of the role of ERα in breast cancer. Most of the published
ChIP-seq and RIME studies for ERα have been performed using the sc-543 antibody from
Santa Cruz Biotechnology[13, 16, 17, 19–21, 32] and the quality and specificity of sc-543 has
made it the ‘golden standard’ for immunoprecipitation experiments. However, this antibody
has recently been discontinued, which has significantly impacted our ability to study ERα biol-
ogy. Here, we have assessed commercially available alternative antibodies. We demonstrate
using ChIP-seq and RIME that the two antibodies 06–935 (Millipore) and ab3575 (Abcam)
perform similarly to sc-543, in terms of sensitivity and specificity. We therefore propose that
these antibodies can replace the sc-543 antibody for immunoprecipitation-based experiments
such as ChIP-seq and RIME to explore ERα function.
Supporting information
S1 Fig. ERα antibody comparison by ChIP-qPCR. ChIP-qPCR analysis for ERα known
binding sites was performed in MCF7 cells in biological duplicates. Results are shown as arbi-
trary units. Antibodies used: sc-543 (Santa Cruz Biotechnology), ab80922 (Abcam), ab3575
(Abcam), sc-514857 (C-3) (Santa Cruz Biotechnology), C15100066 (Diagenode) and 6–935
(EMD Millipore).
(TIF)
S1 File. Main steps of the ChIP-seq analysis. The file provides details for the main steps of
the Bioinformatic analysis of the ChIP-seq data.
(PDF)
S2 File. Quantitative proteomics analysis results. The file contains the protein intensities
across all the different RIME samples based on a label free quantification method using the
Minora algorithm in Proteome Discoverer 2.2.
(XLSX)
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